InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens
InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.
How this was made

The 30-second read
Why it matters
The earnings miss and cash depletion may pressure the stock, but the FDA nod and upcoming equity raise could mitigate downside.
Market read
Micro‑cap biotech earnings with FDA approval; likely short‑term negative sentiment but long‑term upside potential.
What to watch
Cash runway of $19.2M and potential $10M from warrant exercises may support near‑term liquidity.
Background
InspireMD discussed its Q3 2026 results, FDA approval of CGuard Prime for TCAR, and an underwritten equity offering.
Ticker impact
Q3 2026 earnings call disclosed revenue down 11% YoY to $2.2M, net loss of $9.8M and cash of $19.2M, plus FDA approval of CGuard Prime.
likely downside as market prices in the revenue decline and loss
The disclosed financials are materially worse than prior period and no guidance was provided, creating uncertainty for investors.
Market effects
Signals potential headwinds for the vascular device sector as FDA approvals may not translate into immediate sales.
Limited to US biotech investors; no broader regional effect.
Minimal global impact; primarily a micro‑cap specific event.
Counterpoint
The FDA approval could unlock a sizable US market opportunity, offering upside if execution succeeds.
Key entities
- CompanyInspireMD Inc
Medical device maker focused on vascular implants.
- ExecutiveMarvin Slosman
CEO of InspireMD.

